Tranexamic acid is an analogue of the amino acid lysine. It causes antifibrinolytic effect by reversibly binding to lysine receptor sites on plasminogen, thereby preventing its activation and thereby the degradation of fibrin (Patel et al., 2019).
While at lower doses it is a competitive inhibitor of activation of plasminogen into plasmin, at higher doses it is a non-competitive inhibitor of plasmin (Al-Taei et al, 2021).
Ever since the publication of the landmark WOMAN trial, tranexamic
acid has become an integral component in the treatment of postpartum haemorrhage. As a result, there has been a rapid increase in . . .
Please Subscribe to continue reading
